Merck & Co. Inc. (MRK)

76.48
NYSE : Health Technology
Prev Close 78.46
Day Low/High 76.23 / 78.03
52 Wk Low/High 52.83 / 80.19
Avg Volume 11.43M
Exchange NYSE
Shares Outstanding 2.60B
Market Cap 202.86B
EPS 0.90
P/E Ratio 63.21
Div & Yield 2.20 (2.46%)

Latest News

Merck To Acquire Privately Held Antelliq Group

Merck To Acquire Privately Held Antelliq Group

Merck [NYSE:MRK], known as MSD outside the United States and Canada, and privately held Antelliq Group today announced that the companies have signed a definitive agreement under which Merck will acquire Antelliq from funds advised by BC Partners.

Merck And Instituto Butantan Announce Collaboration Agreement To Develop Vaccines To Protect Against Dengue Infections

Merck And Instituto Butantan Announce Collaboration Agreement To Develop Vaccines To Protect Against Dengue Infections

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Instituto Butantan, Sao Paulo, Brazil, a non-profit producer of immunobiologic products for Brazil today announced a collaboration agreement to develop vaccines to protect against...

Who Are the 9 Highest-Paid CEOs and How Much Do They Make?

Who Are the 9 Highest-Paid CEOs and How Much Do They Make?

The CEOs who bring in the most money every year may not be who you expect. Who are the highest-paid CEOs?

Jim Cramer: The Operative Term for This Tape Is Treacherous

Jim Cramer: The Operative Term for This Tape Is Treacherous

Use it to your advantage or don't use it at all.

Merck's President Of Global Human Health Adam H. Schechter To Leave Merck Frank Clyburn Named Chief Commercial Officer And Michael Nally Named Chief Marketing Officer

Merck's President Of Global Human Health Adam H. Schechter To Leave Merck Frank Clyburn Named Chief Commercial Officer And Michael Nally Named Chief Marketing Officer

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Adam H.

Merck KGaA, Darmstadt, Germany Announces FDA Orphan Drug Designation For Bifunctional Immunotherapy M7824 In Biliary Tract Cancer

Merck KGaA, Darmstadt, Germany Announces FDA Orphan Drug Designation For Bifunctional Immunotherapy M7824 In Biliary Tract Cancer

DARMSTADT, Germany, December 10, 2018 /PRNewswire/ -- The information contained is not intended for distribution in the UK    FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer    First...

Merck KGaA, Darmstadt, Germany, In Agreement With Cyclica For AI-augmented Screening Platform To Expand Research Capabilities

Merck KGaA, Darmstadt, Germany, In Agreement With Cyclica For AI-augmented Screening Platform To Expand Research Capabilities

DARMSTADT, Germany, December 6, 2018 /PRNewswire/ -- Not intended for distribution in the U.

Merck To Present At The Citi 2018 Global Healthcare Conference

Merck To Present At The Citi 2018 Global Healthcare Conference

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Robert M.

3 Tips for Trading the Fed's More Dovish Stance

3 Tips for Trading the Fed's More Dovish Stance

Anticipating a weaker dollar thanks to the shift in the Fed, which stocks are most likely to benefit?

European Commission Approves Merck's DELSTRIGO™ (doravirine / Lamivudine / Tenofovir Disoproxil Fumarate), A Once-Daily Fixed-Dose Combination Tablet As A Complete Regimen And PIFELTRO™ (doravirine), An NNRTI, Both For The Treatment Of HIV-1 In Appropriate Patients

European Commission Approves Merck's DELSTRIGO™ (doravirine / Lamivudine / Tenofovir Disoproxil Fumarate), A Once-Daily Fixed-Dose Combination Tablet As A Complete Regimen And PIFELTRO™ (doravirine), An NNRTI, Both For The Treatment Of HIV-1 In Appropriate Patients

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved DELSTRIGO™ and PIFELTRO™ for the treatment of HIV-1 infection.

Here's What's Actually Working as the Market Sells Off: Charts

Here's What's Actually Working as the Market Sells Off: Charts

Stocks are getting hammered ahead of the Thanksgiving holiday. Here's what's still holding up.

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer pushes higher on price increases.

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Pharma could be the best parking spot for your money if the market keeps trending downward.

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Shares of the New York City-based pharmaceutical giant are rising on Monday.

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.

Merck KGaA, Darmstadt, Germany, And Pfizer Provide Update On Avelumab In Platinum-Resistant/Refractory Ovarian Cancer

Merck KGaA, Darmstadt, Germany, And Pfizer Provide Update On Avelumab In Platinum-Resistant/Refractory Ovarian Cancer

DARMSTADT, Germany and NEW YORK, November 19, 2018 /PRNewswire/ -- Not intended for UK-based media     Merck KGaA, Darmstadt, Germany, and Pfizer Inc.

Putting the Markets in Focus: Cramer's 'Mad Money' Recap (Thursday 11/15/18)

Putting the Markets in Focus: Cramer's 'Mad Money' Recap (Thursday 11/15/18)

Jim Cramer says perception is determining how stocks trade right now -- and there's a lot of negativity.

Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared To Chemotherapy In Patients With Advanced Esophageal Or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)

Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared To Chemotherapy In Patients With Advanced Esophageal Or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Phase 3 KEYNOTE-181 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy in the second-line treatment of advanced or metastatic esophageal or...

Merck Begins Rolling Submission Of Licensure Application For V920 (rVSV∆G-ZEBOV-GP) To U.S. Food And Drug Administration

Merck Begins Rolling Submission Of Licensure Application For V920 (rVSV∆G-ZEBOV-GP) To U.S. Food And Drug Administration

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it has started the submission of a rolling Biologics License Application (BLA) to the U.

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Merck & Co Inc is the #4 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Merck & Co Inc is also a top tier analyst pick among the broader S&P 500 index components, claiming the #24 spot out of 500.

The New #1 Most Shorted Dow Component: Merck

The New #1 Most Shorted Dow Component: Merck

The most recent short interest data has been released for the 10/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

FDA Accepts Regulatory Submission For LYNPARZA® (olaparib) Maintenance Therapy In Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer And Grants Priority Review

FDA Accepts Regulatory Submission For LYNPARZA® (olaparib) Maintenance Therapy In Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer And Grants Priority Review

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

FDA Approves Merck's KEYTRUDA® (pembrolizumab) For The Treatment Of Patients With Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated With Sorafenib

FDA Approves Merck's KEYTRUDA® (pembrolizumab) For The Treatment Of Patients With Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated With Sorafenib

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

Drug Stocks Climb as Investors Digest Midterm Election Results

Drug Stocks Climb as Investors Digest Midterm Election Results

A split Congress is the best-case scenario for the drug industry, several analysts said.

Early Phase 1 Data From Merck's Oncology Pipeline For Investigational Anti-LAG-3 Therapy (MK-4280) And Anti-TIGIT Therapy (MK-7684) To Be Presented At SITC's 33rd Annual Meeting

Early Phase 1 Data From Merck's Oncology Pipeline For Investigational Anti-LAG-3 Therapy (MK-4280) And Anti-TIGIT Therapy (MK-7684) To Be Presented At SITC's 33rd Annual Meeting

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentations of preliminary safety and efficacy data from Phase 1/2 dose finding studies for the company's investigational anti-LAG-3 therapy (MK-4280) and...

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.

What Is the Dow Jones Industrial Average?

What Is the Dow Jones Industrial Average?

The Dow Jones Industrial Average is a price-weighted average of 30 large American publicly traded companies on the stock market.

TheStreet Quant Rating: A- (Buy)